Anti-CD38 Antibody Safe, Effective in Immune Thrombocytopenia
The anti-CD38 monoclonal antibody mezagitamab had similar safety to placebo in patients with persistent or chronic immune thrombocytopenia. The drug also significantly increased platelet counts, a key secondary efficacy endpoint. Platelet response with mezagitamab was rapid — a mean of 4 days among patients who responded, and as fast as 2 days. Treatment with the…
